Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study
Authors:
- Katherine G YoungKYKatherine G Young
- Andrew P McGovernAMAndrew P McGovern
- Rhian HopkinsRHRhian Hopkins
- Thijs T JanszTJThijs T Jansz
- Pedro M CardosoPCPedro M Cardoso
- Rury R HolmanRHRury R Holman
- Ewan R PearsonEPEwan R Pearson
- Andrew T HattersleyAHAndrew T Hattersley
- Angus G JonesAJAngus G Jones
- Kieran DochertyKDKieran Docherty
- Naveed SattarNSNaveed Sattar
- Beverley M ShieldsBSBeverley M Shields
Preprint
Abstract
Objectives To develop and validate a model to predict individual-level benefits of SGLT2-inhibitors for heart failure prevention in people with type 2 diabetes who do not have atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic kidney disease (CKD). Design Population based cohort study. Setting The SGLT2-inhibitor absolute response (SABRE) model estimated individual-level 5-year heart failure benefits using absolute heart failure risk predictions from the previously validated QDiabetes-Heart Failure model, combined with the hazard ratio of SGLT2i-associated hospitalisation for heart failure benefit (HR: 0.63 [95% CI: 0.50 to 0.80]) from trial meta-analysis. The data source was primary care records with linked hospital admission and death records (Clinical Practice Research Datalink, England) from January 2013 to October 2020. Population Adults with T2D without ASCVD, HF or CKD initiating an SGLT2i (n=57,368) or, as a comparator group, DPP4-inhibitors or sulfonylureas (n=111,673). Propensity score weighting and regression adjustment were used to mitigate potential treatment selection bias. Validation of model accuracy was performed by comparing the calibration of predicted versus observed heart failure benefits in those receiving SGLT2i versus comparator therapy. Main outcome measures New-onset heart failure recorded in primary care, linked hospital or death records. Results Amongst 57,368 SGLT2i and 111,673 DPP4i/SU treatment initiations, estimated risk of new-onset heart failure was 30% lower with SGLT2i versus the comparator arm (HR: 0.70 [95% CI: 0.63 to 0.78]), similar to trial meta-analysis for hospitalisation for heart failure. The relative benefit of SGLT2i on heart failure was consistent across all levels of baseline absolute heart failure risk as estimated from the QDiabetes-Heart Failure model (p=0.82 for treatment arm:baseline heart failure risk interaction). 5-year absolute heart failure benefit predictions with SGLT2i ranged from Conclusions SGLT2i can be targeted to individuals with type 2 diabetes without ASCVD/HF/CKD for primary prevention of heart failure using an easily deployed clinical prediction model integrating evidence from clinical trials.Keywords
This publication has 34 references indexed in Scilit:
- A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyThe Lancet, 2025
- Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachDiabetologia, 2024
- Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2024
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology, 2021
- The impact of diabetes on heart failure development: The cardio-renal-metabolic connectionDiabetes Research and Clinical Practice, 2021
- Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAmerican Heart Journal, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 DiabetesJAMA, 2019
- Changes in cardiovascular disease risk and behavioural risk factors before the introduction of a health check programme in EnglandPreventive Medicine, 2016
- Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE studyInternational Congress Series, 2003